The BCL, lymphoma in Balblc mice can be successfully treated with bispecific (antLCD3 x anti-idiotype) antibodies (BSABs). In these experiments, animals were injected intraperitoneally (IP) with 5 x 10s tumor cells (day 0 ) and treated with one single intravenous (IV) injection of 5 p g BSAB (day 9). Because cross-linking of the CD3 complex is not in itself sufficient t o activate resting T cells, the therapeutic success was mainly based on the progressive retargeting of the relatively small cytotoxic T-lymphocyte effector cell pool already in existence in vivo. For this reason, the therapy lost its effectiveness at higher tumor loads. Two possibilities were explored t o treat mice with a higher tumor load (10'tumor cells). First, multiple injections of BSABs were used, but a dose-related monovalent anti-CD3 immunosuppression was induced. This approach was only beneficial when the immune system was able t o recover from the previous injection of BSAB. As a second approach, CD28 costimulation ISPECIFIC ANTIBODIES (BSABs) are able to target Extensive in vivo studies in these models have shown that the therapeutic effect was (1) nearly exclusively mediated by T cells rather than by an antibody-dependent cellular cytotoxicity mechanism; (2) the result of in vivo bridging of T cells and tumor cells, because a mixture of monovalent anti-idiotype and monovalent anti-CD3 was not effective; (3) mediated by both CD4+ and CD8+ T cells, because depletion of one of the subsets reduced in vivo efficacy; (4) partly due to the cytokines interferon-y (IFN-y) and tumor necrosis factor-a released in the vicinity of the tumor cells by the BSAB-mediated T-cell activation process. The former acts directly by inhibiting tumor growth and the latter acts via an indirect mechanism, possibly by activating macrophages.' In most of the experiments, using the BCLl tumor model, animals were injected intraperitoneally (IP) with 5000 tumor cells and treated with a single intravenous (IV) injection of 5 pg BSAB 9 days later. At a higher tumor load, the therapy lost its effectiveness. If this treatment approach were to be used to treat human cancer, the potency of the treatment would have to be enhanced. We therefore examined two possible ways of increasing the efficiency of this kind of treatment: (1) by multiple injections and (2) by costimulation with monospecific antLCD28 antibodies. The idea is that multiple injections will focus several waves of effector T cells on the tumor target. BSABs recognizing the CD3/TCR complex and an epitope on the tumor cell can induce preactivated T cells to lyse the tumor cells. However, resting T cells cannot be activated by crosslinking of their CD3/TCR protein complex alone but require a second signal. As suggested by Jung et al?' this second signal can be provided by cross-linking of the CD28 homodimer. This approach was used in vitro by Bohlen et a16 to activate autologous resting T cells and to lyse autologous chronic lymphocytic leukemic B cells by means of a BSAB (anti-CD3 X anti-CD19) and bivalent anti-CD28 monoclonal antibody (MoAb) combination. The same group extended these in vitro results by using a combination of two BSABs (anti-CD3 X anti-CD19 and anti-CD22 X anti-CD28) in an attempt to further increase the tumor ~pecificity.~ Later on, an identical approach was used by Renner et a18 to cure a xenografted human Hodgkin tumor in SCID mice by means of two BSABs (anti-CD3 X anti-CD30 and anti-CD30 X anti-CD28) in a single injection. We extend here these studies to a syngeneic animal model, showing that the efficacy of the treatment could be further increased by repeated injections and/or by anti-CD28-induced costimulation.
with one single intravenous (IV) injection of 5 p g BSAB (day 9). Because cross-linking of the CD3 complex is not in itself sufficient t o activate resting T cells, the therapeutic success was mainly based on the progressive retargeting of the relatively small cytotoxic T-lymphocyte effector cell pool already in existence in vivo. For this reason, the therapy lost its effectiveness at higher tumor loads. Two possibilities were explored t o treat mice with a higher tumor load (10'tumor cells). First, multiple injections of BSABs were used, but a dose-related monovalent anti-CD3 immunosuppression was induced. This approach was only beneficial when the immune system was able t o recover from the previous injection of BSAB. As a second approach, CD28 costimulation ISPECIFIC ANTIBODIES (BSABs) are able to target B polyclonal immune effector cells on tumor cells and are considered a new, powerful reagent for cancer immunotherapy. Indeed, several groups have used BSABs successfully to target effector cells (T and natural killer [NK] cells) on a variety of target cells in vitro. ' We have previously reported on the use of BSABs in the treatment of two wellcharacterized B-cell lymphoma models.'** These BSABs were hybrid-hybridoma antibodies with dual specificity for the T-cell receptor (TCR)/CD3 complex and for the tumorspecific idiotype of the surface IgM expressed by the tumor cells.
Extensive in vivo studies in these models have shown that the therapeutic effect was (1) nearly exclusively mediated by T cells rather than by an antibody-dependent cellular cytotoxicity mechanism; (2) the result of in vivo bridging of T cells and tumor cells, because a mixture of monovalent anti-idiotype and monovalent anti-CD3 was not effective; (3) mediated by both CD4+ and CD8+ T cells, because depletion of one of the subsets reduced in vivo efficacy; (4) partly due to the cytokines interferon-y (IFN-y) and tumor necrosis 0 I996 by The American Society of Hematology. OOO6-497 1/96/87 I O-OO37$3.00/0 together with BSABs were used in an attempt t o activate resting T cells, ultimately enlarging the effector T-cell pool. However, we were repeatedly unsuccessful in attempts t o improve our in vivo results using young, naive animals in which the majority of T cells are of the naive phenotype. Only when animals were primed t o induce the memory Tcell type was a significantly better outcome observed, and then only with multiple injections of BSABs and antLCD28 monoclonal antibodies (MoAbs), rather than with BSAB or anti-CD28 MoAb alone. These results suggest that this combination was able t o activate memory and effector T cells and t o focus them on the tumor, but was unable t o activate naive T cells fully. The in vivo potency of the BSAB and CD28 costimulation was shown by the fact that one-tenth of the quantity of BSAB was required t o cure animals with 20 times the tumor load. 0 1996 by The American Society of Hematology.
factor-a released in the vicinity of the tumor cells by the BSAB-mediated T-cell activation process. The former acts directly by inhibiting tumor growth and the latter acts via an indirect mechanism, possibly by activating macrophages.' In most of the experiments, using the BCLl tumor model, animals were injected intraperitoneally (IP) with 5000 tumor cells and treated with a single intravenous (IV) injection of 5 pg BSAB 9 days later. At a higher tumor load, the therapy lost its effectiveness. If this treatment approach were to be used to treat human cancer, the potency of the treatment would have to be enhanced.
We therefore examined two possible ways of increasing the efficiency of this kind of treatment: (1) by multiple injections and (2) by costimulation with monospecific antLCD28 antibodies. The idea is that multiple injections will focus several waves of effector T cells on the tumor target. BSABs recognizing the CD3/TCR complex and an epitope on the tumor cell can induce preactivated T cells to lyse the tumor cells. However, resting T cells cannot be activated by crosslinking of their CD3/TCR protein complex alone but require a second signal. As suggested by Jung et al?' this second signal can be provided by cross-linking of the CD28 homodimer. This approach was used in vitro by Bohlen et a16 to activate autologous resting T cells and to lyse autologous chronic lymphocytic leukemic B cells by means of a BSAB (anti-CD3 X anti-CD19) and bivalent anti-CD28 monoclonal antibody (MoAb) combination. The same group extended these in vitro results by using a combination of two BSABs (anti-CD3 X anti-CD19 and anti-CD22 X anti-CD28) in an attempt to further increase the tumor ~pecificity.~ Later on, an identical approach was used by Renner et a18 to cure a xenografted human Hodgkin tumor in SCID mice by means of two BSABs (anti-CD3 X anti-CD30 and anti-CD30 X anti-CD28) in a single injection. We extend here these studies to a syngeneic animal model, showing that the efficacy of the treatment could be further increased by repeated injections and/or by anti-CD28-induced costimulation.
MATERIALS AND METHODS

Mice.
Male Balb/c mice (8 to 10 weeks old) were purchased from Charles River Wiga gmbh (Sulzfeld, Germany; via the Broekman Institute, Heesch, The Netherlands).
The Balb/c-derived B-cell tumor BCLl was used in the in vitro and in vivo experiments, as described previo~sly?.~ These cells express surface IgMX.
The anti-CD28 antibody is a hamster antimouse MoAb binding to the CD28 molecule present on most T cells. A control hamster anti-DNP MoAb was used in some experiments.
Both hybridoma cell lines were kindly provided by Dr J.P. Allison (University of California, Berkeley, CA). The production and purification of the B1 X 7D6F (functional;
anti-BCL1 x anti-CD3) BSAB has been described in detail.* Two ideal control BSABs were used throughout the study, ie, B 1 X 7D6M (mismatch), which is able to bind to BCLl idiotype protein but lacking CD3-specificity, and the E4 X 7D6F BSAB, which is directed against the idiotype of the 38C13 mouse B-cell tumor and the CD3 complex. . Tumor-free control mice were injected with identical amounts. Spleens were removed 1 to 21 days later and, after a cell suspension had been made, the proliferative capacity was assessed. For this assessment, 5 X l@ spleen cells were placed in round-bottomed microwell plates and stimulated with 500 n g / d Con A (Boerhinger Mannheim, Mannheim, Germany). A proliferation assay was also performed using mitomycin-c-treated BCL, cells.' Tumor cells were placed in microwell plates at l@/ well and cocultured in standard medium with 5 X ld spleen cells in the presence or absence of BSAB at a concentration of 100 ng/ mL. After 3 days, the wells were pulsed with (3H) thymidine for 8 hours before harvesting. All assays were performed in a final volume of 200 pL standard medium, consisting of RPMI 1640 (Life Technologies, Ghent, Belgium), 2% a calf serum (Hyclone, Greiner, Westmalle, Belgium), and other additives? T-cell proliferation with BSAB-and anti-CD28-induced costimulation. Cocultures were performed as described in the previous section, except that purified splenic T cells were used instead of whole spleen,) together with BCLl tumor cells at a 111 ratio. All antibodies were used at a final concentration of 100 ng/mL, as indicated.
Animals treated with BSAB alone were injected IP with 5 X l@ or 105 BCL, tumor cells and treated at day 9 with IV injections of BSAEL The delay between the consecutive injections varied between 3 and 21 days. Animals treated with BSAB and anti-CD28 MoAb together were injected IP with 5 x 104 or 10s tumor cells. Mice were injected IV with B1 X 7D6F, anti-CD28 MoAb, or a combination of both (coinjection) from day 9 for 4 consecutive days (except where otherwise indicated). Animals were considered to be cured if they survived beyond day 150 and no idiotype protein was detected in their serum.3 The Mann-Whitney
U test was used to analyze the significance between groups.
In some experiments, Balb/c mice were immunized against the EL4 T cell lymphoma by IP injections of 25 X lo6 cells suspended in 0.5 mL of PBS. They received 2 injections at an interval of 10 days; the last injection was 3 weeks before inoculation with BCL, tumor cells.
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RESULTS
Eficacy of BSAB (anti-idiotype X anti-CD3) is tumor load
As previously reported:' the injection of 5 pg B1 x 7D6F was repeatedly seen to cure nearly 100% of animals injected with 5 x lo' tumor cells 9 days before treatment. This late point of time in treatment was chosen for two main reasons. First, treatment with equivalent amounts of monovalent or bivalent anti-idiotypic antibodies, in identical experimental conditions, had no therapeutic effect (our own unpublished results). We concluded that BSABs were superior to anti-idiotypic antibodies for this purpose. Secondly, it mimics more closely the treatment of an established tumor. However, when larger numbers (20X higher) of tumor cells were injected, one injection of 5 pg BSAB was unable to effect a cure (Fig 1) . Initial experiments using multiple injections of BSAB. One possible way to increase the efficacy of the BSAB treatment was to use multiple injections. Animals were therefore injected four times with 5 pg B1 X 7D6F or B1 X 7D6M control antibody, with a delay of 5 days between consecutive injections. As expected, survival of animals injected one or four times with the control bi-isotypic antibody B 1 X 7D6M did not differ from that of animals injected with PBS (Table  1) . However, animals receiving four injections of 5 pg B1 X 7D6F had no better mean survival time (MST) or increased survival rate than did the animals who were injected once. 
DAYS AFTER TREATMENT
Apparently, the last three injections were of no benefit to the animals.
Induction of a dose-dependent hyporesponsiveness with (anti-Id X anti-CD3) BSAB. To investigate how multiple injections of BSAB failed to increase the efficacy of the treatment, we restimulated in vitro spleen cells from animals previously injected with BSAB. In these experiments, normal Balb/c or tumor-bearing animals were injected with 5 pg B1 X 7D6F or PBS, and their spleens were removed after 1,7, 14, or 21 days. The spleen cells were restimulated in vitro with Con A or were cocultured with mitomycin-ctreated BCL, cells and stimulated with B1 X 7D6F. The proliferation was compared with that of freshly isolated control spleen cells. In normal mice injected with BSAB, profound immunosuppression was induced, as evidenced by the strongly decreased proliferation to Con A and in the coculture experiment (Fig 2A and C) . The response reached normality only after 3 weeks. The situation is somewhat more complicated in tumor-bearing animals because the spleen (major site for growing BCL, cells) becomes invaded by tumor cells.
In tumor-bearing animals injected with PBS, the proliferative capacity of the spleen cells decreased dramatically ( Fig  2B and D) between days 7 and 14. This severe immunosuppression in BCL,-bearing animals has been described pre- viously.'o On day 21, the spleen was visibly invaded by tumor cells; consequently, the large incorporation of 'Hthymidine was no longer representative for T-cell proliferation. On the other hand, spleen cells from BCL,-bearing animals treated with B1 X 7D6F showed a reduced proliferation to Con A and in the coculture experiments up to 14 days, but this difference had disappeared by day 21. We concluded that one injection in vivo of 5 pg B1 X 7D6F was able to induce a state of hyporesponsiveness for at least 2 to 3 weeks. Figure 3 shows the results from an identical set-up (except that the spleens were removed at days 1,3, and 7 after BSAB injection) to show dose-dependent induction of immunosuppression. Animals injected with 0.5 pg BSAB recovered earlier than those injected with 5 pg. In other words, the efficacy of subsequent BSAB injections will depend on the time delay between injections and on the amount (Fig 4) . It is probable either that the cumulative dose was too low or that the delay between injections was too long. Only in the p u p s treated with the intennediate amount (1.5 pg x 3) of BSAB did a survival rate of 60% appear, compared with no survival for the p u p treated once. It seems that an optimum exists between the amount injected and the delay between injections that is necessary for T-cell recovery.
BSAB and anti-CD28 MoAb induce T-cell proliferation when bridged to tumor cells (in the absence of accessory cells). Because T-cell costimulation has attracted much attention with regard to the generation of an optimal T-cell response, we investigated the role of CD28 costimulation in T-cell targeting by BSAB. In coculture experiments (Fig 5 ) of BCL, tumor cells and purified T cells, no proliferation was observed after the addition of B 1 x 7D6F or anti-CD28 alone or with control antibodies E4 X 7D6F or B1 X 7D6M. The addition of bivalent anti-CD28 MoAb to the medium induced a remarkable proliferation of T cells, which was not the case with control hamster anti-DNP MoAb. These experiments were repeated five times and had identical results. Checkerboard-titration of both antibodies showed that proliferation was maximal with a ratio of anti-CD28BSAB between 111 and 113 (data not shown). Kinetic studies also showed that the anti-CD28 MoAb should be added to the culture medium together with the BSAB. The addition of 
antLCD28 (Fig 6) 24 hours later did not result in enhanced proliferation. Apparently, optimal proliferation requires the simultaneous delivery of the two signals.
In vivo results using BSAB and anti-CD28 MoAb-induced costimulation in naive animals. Based on the in vitro coculture experiments, the combination of BSAB and anti-CD28 costimulation was tested in vivo. Animals were treated with 5 pg BSAB 2 anti-CD28. However, the addition of anti-CD28 to B1 X 7D6F did not improve survival compared with injection of B 1 X 7D6F alone (Table 2A) . In subsequent experiments (Table 2B and C), multiple injections (4X) with a low dose (100 to 500 ng) of BSAB ? anti-CD28 were administered, but again without any difference between animals injected with or without anti-CD28.
In vivo results using BSAB and anti-CD28 costimulation in primed animals. The results shown in Table 2 were disappointing but were in strong contrast to the in vitro coculture experiments ( Figs 5 and 6 ), thus encouraged us to continue. Therefore, naive animals were pretreated with two injections of allogeneic ELA cells, with the latest injection administered 3 weeks before injection of the BCL, tumor cells. Animals were treated with multiple injections of BSAB in increasing amounts (10 to 100 to 500 @dose of each antibody). As can be seen in Table 3A, there was a clearly enhanced MST in all p u p s treated with the combination, even in the group injected with the smallest amount . The delays between injections were 3, 7. and 21 days, respectively. In all groups, treatment was started at day 9 after tumor cell inoculation. treated with multiple injections of 100 or 500 ng of both antibodies. Here, animals treated once with 5 pg BSAB + anti-CD28 also showed an enhanced survival and MST as compared with the groups treated with BSAB alone (Table 3B) . These results, using low amounts of BSAB and anti-CD28, were confirmed (Table 3C) 
DISCUSSION
The model system used in this and previous2 studies is the transplantable B-cell lymphoma BCL,, a highly malignant tumor in which transfer of a single tumor cell to a syngeneic Balb/c mice is capable of causing death. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From (lo5 tumor cells) and 25 (5 X lo3 tumor cells) and is a barrier for anti-idiotypic or anti-Id X anti-CD3 BSAB-based immunotherapeutic approaches. Because we wanted to explore how the efficiency of the BSAB therapy could be enhanced, the limits of the immunotherapy must be rather tested by varying the size of the initial tumor inoculum rather than by further delaying the therapy. In our initial studies, animals received 5 X lo3 tumor cells IP and were treated with a single injection of BSAB IV at day 9. In this study, animals are injected IP with lo5 tumor cells (20X higher) and treatment started at day 9, as before. Considering the high amount of tumor cells injected and the low amounts of BSABs used (see further), we aimed to explore the limits of this specific therapeutic approach. In previous studies using this model, one dose of 5 pg BSAB was reproducibly able to cure nearly all animals receiving 5 x io3 tumor cells.
However, this dose was insufficient when lo5 tumor cells were inoculated (Fig 1) . Therefore, we evaluated two possible ways to increase the efficacy of the BSAB therapy, ie, the use of multiple injections of BSAB alone or combined with anti-CD28 MoAbinduced costimulation. Unexpectedly, multiple injections (4X 5 pg) administered with a delay of 5 days between consecutive injections were not able to improve survival or increase MST compared with the animals injected once (Table l). Because no difference in MST between one and four injections was observed, the last three injections apparently did not have any effect. In vitro analysis of the proliferative capacity of spleen cells on BSAB-treated animals showed a dose-dependent hyporesponsiveness. Identical experiments For personal use only. on October 27, 2017. by guest www.bloodjournal.org From using the parental bivalent anti-CD3 MoAb showed the same immunosuppression, except that the induction was somewhat earlier and more profound, but recovery was reached earlier (data not shown).
Activation of T cells by bifunctional intact IgG BSAB is due to an Fc-mediated mechanism that does not necessarily require the presence of target cells (cross-linking CD3 to FcRy, expressed by APC) and a mechanism that is Fc-independent and requires the presence of cells expressing the target Ag (cross-linking CD3 to the target Ag)." Because normal mice injected with BSAB were also immunosuppressed, the former mechanism was most likely involved. The in vivo immunosuppressive activity of the bivalent 7D6 anti-CD3 MoAb was recently described by Flamand et a1," but in their experiments, a rather high dose of 2X 25 pg was used. Here, despite the low amount ( 5 pg) and CD3-monovalency of the biisotypic BSAB used in our experiments, immunosuppression is induced and was not due to contaminating bivalent anti-CD3, because each batch of BSAB was carefully checked for purity. Moreover, the biisotypic Fc-tail of our BSAB was not efficient in performing ADCC or inducing activation of T cells in a whole spleen mononuclear cell suspension. This immunosuppressive effect is particularly important for those groups who want to use anti-CD3 based BSABs for human therapy and was probably the cause of the failure of the first multiple injections experiments in this study. Nevertheless, the second Fcindependent T-cell activation mechanism is still the most important because animals were cured with the real B1 X 7D6F bispecific antibody and not with the mixture of B1 X 7D6M and E4 X 7D6F antibodies.
In subsequent trials, the delay between injections was adapted to the injected dose. A cumulative dose of 4.5 pg (3X 1.5 pg) resulted in 60% survival and increased MST. This result was better than when one or three injections of times 5 pg were used, clearly indicating that the outcome was not determined by the amount used but rather by the timing of the injections. Thus, it is possible to bypass the immunosuppression by using small amounts of BSAB administered with a certain delay, allowing T cells to recover. Although no experiments were performed with BSABs without Fc-tail [F(ab'M, the possibility exists that they could avoid immunosuppression. Their more difficult production, lower stability, and shorter half-life in vivo are other points to be considered.
A two-signal model for T-cell activation was proposed by Bretscher and Cohni3 and recently extended by Jenkinsi4 and S~hwartz.'~ In this model, the first signal through the TCW CD3 is necessary but not sufficient to induce long-term Tcell activation and cytokine secretion. A second costimulatory signal is essential for T-cell expansion, lymphokine secretion, and generation of effector functions. If this signal 2 is not delivered, T cells enter a state of unresponsiveness. This is particularly true when bivalent anti-CD3 MoAb are sed,'^.'^ but is not described for univalent anti-CD3, as used in BSAB.
The most potent T-cell costimulatory effect is found when anti-CD28 MoAb are used in conjunction with suboptimal amounts of anti-CD3.i"i9 CD28-induced T-cell proliferation is interleukin-2 (IL-2)-dependent and results from the induction of IL-2 transcription" and stabilization of cytokine RNA." Therefore, we investigated the use of anti-CD28 as costimulatory agent, together with anti-Id X anti-CD3 BSABs.
In a first series of experiments using this strategy, we were unable to improve our results (Table 2) . One reason could be that we used rather young SPF animals in which the majority of T cells are of the naive phenotype. Indeed, the majority of mature peripheral CD4' T cells are resting and can be devided into naive and memory subsets, based on whether or not they have encountered their specific antigen. Both cell types can be discriminated by membrane markers. Naive CD4' T cells express high levels of CD45RJ3 (CD45RA in human). Memory CD4' T cells express low levels of CD45RB, but have higher levels of several adhesion molecules such as intercellular adhesion molecule-1 (ICAMl), leukocyte function-associated molecule-1 (LFA-l), CD2, LFA-3 and others.22 Activated effector CD4' T cells express a phenotype similar to that of resting memory T cells. Both naive and memory T cells have distinct patterns of cytokine secretion. Naive T cells only secrete IL-2 in low amounts on initial stimulation, whereas memory cells can produce many cytokines (IL-4 and IFN-y), in addition to greater levels of IL-LZ3 Moreover, when mouse CD4+ or CD8' T cells were stimulated in vitro by immobilized bivalent anti-CD3 in the presence of anti-CD28 MoAb, it appeared that only the CD4' T cells responded to stimulation. However, when IL-2 was added to the CD8+ T cells, they also proliferated (our own unpublished observations). These results indicate that, although both T-cell populations were activated, only the CD4' T-cell population produces sufficient amounts of IL-2 to stimulate its own proliferation. The CD8' population requires IL-2 from an extemal, eg, CD4' T-cell derived, source.
Young animals, with a large pool of naive T cells and stimulated by BSAB, probably do not produce sufficient IL-2 for full proliferation of CD4' and CD8' T cells, even with the costimulatory anti-CD28 stimulus, as described by Kuyper et al. 24 These investigators concluded that CD4' naive T cells still have more stringent TCWCD3 activation requirements than do memory cells, even in the presence of CD28 costimulation.
An identical conclusion was formulated by Renner et a18 using two BSABs (anti-CD3 X anti-CD30 and anti-CD28 X anti-CD30) against Hodgkin cells. No in vitro cytotoxicity was detectable with the combination of both BSABs, unless the T cells were preactivated.
In analogy, coculture experiments using spleen cells from naive or primed animals showed a much higher proliferative and cytotoxicity capacity with the latter (data not shown).
Both FishePs and Dubey26 concluded from their studies using the ICAM-1 : LFA-1 and B7:CD28 costimulatory pathways that an efficient naive T-cell response requires both a strong TCR signal and "more than one" costimulatory signal. Azuma cross-linking, reported that the highest activity was detected within the memory CD4' and CD8+ T-cell pool.
To examine if any in vivo effect could be seen when T cells are in a more differentiated (memory T-cell) state, animals were primed with allogeneic EL4 cells. To avoid interference of the allogeneic reaction itself, the last (of 2) injections was administered 21 days before tumor inoculation. In this experiment, primed animals (Table 3 ) who received both BSAB and anti-CD28, but not nonprimed animals, showed increased survival and MST. It was remarkable that a cumulative dose of 400 ng of both antibodies was able to cure 60% to 70% of the animals. It should be stressed that, in these primed animals, multiple injections of B1 X 7D6F only at low dose did not result in enhanced survival. In contrast, the combination of BSAB and anti-CD28 was effective, showing that the EL4 priming not only induced an expected higher proportion of anti-ELA allogeneic CTLs, but also an additional T-cell population, probably memory T cells, were engaged in the successful treatment. An even better result would be expected if more consecutive injections were administered to continuously drive the T-cell proliferation that ultimately destroys the tumor cells.
With this approach, we were able to cure a significant number of animals with a relatively small amount of BSABs and anti-CD28 (400 ng cumulative dose of both). This is particularly important because a limiting step in this form of immunotherapy is the production of sufficient amounts of BSABs. We proved here that, in combination with anti-CD28, 10 times less BSAB was required to cure animals with a 20 times higher tumor burden, compared with our previous results? A second important point is that it is not absolutely necessary to use two BSABs (antitumor X anti-CD3 and antitumor X anti-CD28), as proposed by others.',' Although these investigators argue that the specificity of the treatment could be increased by using two BSABs, no definitive proof to this interesting statement has been given. Our final conclusion is that treatment of anti-Id X anti-CD3 BSAB alone primarely retargets available cytotoxic or cytolytic T cells. The contribution of newly activated T cells with multiple injections will be minimal, considering the expected immunosuppression. Nevertheless, multiple injections of BSAB alone can increase the efficacy, provided enough time is available for complete recovery of the T cells.
Moreover, our results suggest that the use of the costimulatory anti-CD28 pathway combined with BSABs preferentially targets the activated, resting memory T-cell pool plus already available effector cells towards the tumor cells.
A further goal should be to use the naive T-cell pool as well, but these cells demand more stringent requirements for full activation.
In finalizing this report, Renner et alZ9 showed by in vitro work that the cytotoxicity induced by CD3 and CD28 BSABs was preferentically mediated by the CD45RO' memory T-cell pool, supporting the findings of our in vivo experiments.
